Analysis of the mechanism of action of capmatinib targeted drug

Capmatinib (Capmatinib) is a selective MET inhibitor, a small molecule targeted drug, mainly used to treat patients with MET gene mutations (especially METexon14 skipping mutation or METamplification) non-small cell lung cancer (NSCLC) patients. METgene mutations can lead to continued abnormal activation of MET protein, thereby driving tumor cell proliferation, migration and resistance to apoptosis. Capmatinib precisely inhibits the activity of MET receptor tyrosine kinase, blocking this abnormal signaling pathway from the source and effectively inhibiting tumor growth.

Under normal physiological conditions, the MET receptor binds to its ligand HGF (hepatocyte growth factor), which activates a series of downstream pathways, such as PI3K/AKT, RAS/ERK and STAT pathways, thereby regulating cell growth, survival and migration. In tumor patients, MET gene mutations or amplifications will cause the continuous activation of this pathway. Even without stimulation from the ligand HGF, the signal can "run spontaneously" and trigger malignant growth. Capmatinib can efficiently bind to the kinase domain of MET, inhibit its autophosphorylation process, and thus terminate the initiation of the entire signal chain.

Capmatinib not only has a high inhibitory effect on MET mutant tumor cells, but is also effective against some cancer types with MET amplification. Especially in NSCLC patients with MET exon 14 skipping (METexon 14skipping) mutations, the therapeutic effect is more significant. This mutation will lead to the impairment of the degradation function of MET protein, causing its abnormal accumulation in cells, thereby promoting canceration. Capmatinib targets this molecular weakness and has become one of the important drugs for precision treatment.

In addition, the clinical application of capmatinib also shows that it has good central nervous system penetration and may also be effective in patients with brain metastases. Due to its high specificity, capmatinib has less impact on non-target proteins, so its side effects are relatively controllable. Common side effects include edema, nausea, decreased appetite, and fatigue. With the accumulation of more clinical data and the exploration of combination regimens, capmatinib is expected to exert greater potential in precision treatment.

Reference materials:https://www.novartis.com/our-products/pipeline/capmatinib